1. Academic Validation
  2. Synthesis and Development of Highly Selective Pyrrolo[2,3- d]pyrimidine CSF1R Inhibitors Targeting the Autoinhibited Form

Synthesis and Development of Highly Selective Pyrrolo[2,3- d]pyrimidine CSF1R Inhibitors Targeting the Autoinhibited Form

  • J Med Chem. 2023 May 25;66(10):6959-6980. doi: 10.1021/acs.jmedchem.3c00428.
Thomas Ihle Aarhus 1 2 Frithjof Bjørnstad 1 2 Camilla Wolowczyk 3 Kristin Uhlving Larsen 4 Line Rognstad 2 Trygve Leithaug 2 Anke Unger 5 Peter Habenberger 5 Alexander Wolf 5 Geir Bjørkøy 3 Clare Pridans 6 Jan Eickhoff 5 Bert Klebl 5 Bård H Hoff 2 Eirik Sundby 1
Affiliations

Affiliations

  • 1 Department of Materials Science & Engineering, Norwegian University of Science and Technology (NTNU), NO-7491 Trondheim, Norway.
  • 2 Department of Chemistry, Norwegian University of Science and Technology (NTNU), NO-7491 Trondheim, Norway.
  • 3 Department of Biomedical Laboratory Science, Norwegian University of Science and Technology (NTNU), NO-7491 Trondheim, Norway.
  • 4 Skogmo IndustriomrÅde, Industrivegen 50, N-7863 Overhalla, Norway.
  • 5 Lead Discovery Center GmbH, Otto-Hahn-Straße 15, 44227 Dortmund, Germany.
  • 6 University of Edinburgh Centre for Inflammation Research, Queen's Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, U.K.
Abstract

Colony-stimulating factor-1 receptor (CSF1R) is a receptor tyrosine kinase that controls the differentiation and maintenance of most tissue-resident macrophages, and the inhibition of CSF1R has been suggested as a possible therapy for a range of human disorders. Herein, we present the synthesis, development, and structure-activity relationship of a series of highly selective pyrrolo[2,3-d]pyrimidines, showing subnanomolar enzymatic inhibition of this receptor and with excellent selectivity toward other kinases in the platelet-derived growth factor receptor (PDGFR) family. The crystal structure of the protein and 23 revealed that the binding conformation of the protein is DFG-out-like. The most promising compounds in this series were profiled for cellular potency and subjected to pharmacokinetic profiling and in vivo stability, indicating that this compound class could be relevant in a potential disease setting. Additionally, these compounds inhibited primarily the autoinhibited form of the receptor, contrasting the behavior of pexidartinib, which could explain the exquisite selectivity of these structures.

Figures
Products